Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease
NCT05463133Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2022
- Primary completion
- Dec 2032
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab, emapalumab in chronic granulomatous disease (CGD), sponsored by National Institute of Allergy and Infectious Diseases. Started Jul 2022; status: recruiting.
02
Drugs
tocilizumabemapalumab
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT05463133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463133.